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Objectives: Adherence to treatment guidelines for uncomplicated malaria is critical to the success of malaria case
management. Poor adherence has implications for increased malaria burden, in view of the risk of widespread
parasite resistance and treatment failures. This study analyzed the diagnostic and prescription pattern for
uncomplicated malaria at two public health facilities, south east Nigeria, to assess the current state of compliance
to policy guidelines on the use of artemisinin-based combination therapy (ACT).
Methods: Retrospective audit of patients’ records, treated for uncomplicated malaria, between the months of
January and March 2013, was undertaken at two public health facilities. Demographics, diagnostic information,
medication and cost data were extracted. Questionnaires were distributed to providers to assess their malaria
treatment intent. Data from the facilities were analyzed and compared for similarities and systematic differences,
and conformity to malaria treatment policy, in terms of laboratory diagnosis, use of ACT, co-medication and cost
of medication.
Results: A total of 2,171 records of patients who had been treated for uncomplicated malaria were analyzed. Of
these, 1066 (49%) were sent for laboratory confirmation of malaria using mostly microscopy, out of which 480
(45%) tested positive. 51% (1105) of the prescriptions was on the basis of presumptive treatment. 58% of slide
negative results received antimalarial drugs. 93% of patients received ACT, with artemether-lumefantrin, AL (50.5%)
as the most prescribed antimalarial drug. Monotherapy accounted for 7% of prescriptions, comprising mostly
sulphadoxine + pyrimethamine, SP (46.5%) and monotherapy artemisinin, AS (29.2%). 97% of the prescriptions
received at least one co-medication. Antibiotics were prescribed to 50% of patients. Overall, median cost of
medication was N1160.00 (US$7.48 (US$0.19 - 267.87) per case, higher in tertiary than the secondary facility. There
were significant variations in treatment practices between the two facilities.
Conclusion: Evidence suggests good compliance to policy on the use of ACT as first line treatment for
uncomplicated malaria. However, there exists significant scope for improved diagnosis and rational drug use, to
enhance accuracy of treatment, reduced wastages and risks of adverse drug reactions, in line with the goals of ‘test
and treat’ policy of malaria case management.
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Case management remains a major strategy for effective
control of malaria, comprising diagnosis and prompt
treatment with effective antimalarial drugs. In recogni-
tion of its high efficacy and potential for preventing de-
velopment of parasite, ACT was recommended for the
first line treatment for uncomplicated malaria in 2001
[1]. However, in view of the need to achieve efficiency in
malaria treatment and enhance the goals of case man-
agement, the World Health Organisation (WHO) rec-
ommended the test, treat and track (TTT) policy, which
emphasises improved diagnosis of malaria infection,
prompt treatment with effective antimalarial drugs and
regular monitoring through routine information system
to ensure effective implementation [2,3]. Subsequently
many malaria endemic countries in Africa adopted the
policy, highlighting the importance of parasitological
diagnosis using either microscopy or rapid diagnostic
tests (RDTs) for malaria treatment, in all age groups and
in all epidemiological settings [3,4]. This led to an in-
creased supply of RDT. However, major challenge to im-
plementation of policy guidelines has remained that
change in policy recommendations does not always
translate to immediate and effective change at health
care provider levels and hence, inadequate quality case
management at the point of care [5]. Consequently, in-
appropriate practices in the provision of malaria treatment
have been reported among healthcare providers, from fa-
cilities in many malaria settings [5-8]. This constitutes
non-adherence to treatment guidelines, contributing to
undermining the goals of malaria treatment policy.
Adherence to policy guidelines by healthcare providers
and patients is essential for achieving the success of this
policy [3,9]. Studies in developing countries suggest that
many years after the introduction of ACT, inappropriate
prescription and use of antimalarial drugs persist, at
both public and private health facilities [6-9]. With bet-
ter exposure to information, it is expected that health
workers in public facilities would have better access to
malaria treatment guidelines, and be more likely to ad-
here to recommended strategy for uncomplicated mal-
aria [7]. Although the public health facilities, more than
the private sector, are known to largely conform to pol-
icy on the use of antimalarial drugs [10,11], reports indi-
cate substantial inappropriate treatment practices, such
as presumptive treatment, treatment of slide -negative
results, co-medication (poly-pharmacy), use of low qual-
ity and expensive ACT and monotherapy [7-9]. These
lead to wastages and inefficiency in the implementation
of malaria case management, thereby increasing the risk
of widespread resistance and treatment failures.
A study in Kenya [12] demonstrated how lack of adher-
ence to treatment guidelines was associated with inappro-
priate prescription practices. The use of sub-therapeuticdoses of drugs contributes to the risk of developing para-
site resistance [13]. Drug regimens with long duration of
treatment, such as monotherapy artesunate also contrib-
ute to poor adherence [8,14]. Concomitant medications
further contribute to inappropriate prescription through
polypharmacy, which increases risks of drug interactions,
adverse drug reactions, non-adherence and treatment fail-
ures, in addition to high cost of care [11]. Presumptive
treatment in health facilities have been shown to be wide-
spread even with the availability of diagnostic instruments.
Evidence also suggests frequent use of antimalarial drugs
by health workers on slide-negative results [3,5,7,15].
Given the substantial misdiagnosis of febrile patients for
malaria cases, using presumptive diagnosis, the use of
antimalarial drugs under the current policy involving
the use of more expensive ACT, represents substantial
economic losses.
Several factors have been identified to be responsible
for the non-adherence of prescribers to recommended
guidelines. Inadequate supply of recommended drugs,
unnecessary use of more expensive recommended drugs,
continuous availability of monotherapy, staff shortages
and high work load, as well as contradicting training
messages that confuse workers [9,16], have been re-
ported. These represent supply-side factors which limit
effective implementation of malaria treatment policy. In
Nigeria, although change in policy to the use of ACT was
introduced in 2005 [17], inappropriate practices have been
reported by many studies [7,10]. Understanding these is-
sues is essential for generating information for implement-
ing strategies to improve effective malaria treatment. This
study was aimed to describe and assess the diagnostic and
treatment patterns for uncomplicated malaria at two pub-
lic health facilities in Nigeria, and determine current con-
formity to policy guidelines.
Methods
Study population
The study was undertaken in Anambra state, south-east
Nigeria, with a total population of 4.18 million inhabitants
by 2006 Nigerian census, considered as the second most
densely populated state in the country (1,500 – 2000 per-
sons per km2). Divided into three senatorial zones, the
state has 21Local government Areas (LGAs). The people,
who are predominantly ethnic Ibos, are involved in farm-
ing as the main occupation, while a significant number is
into trading and commerce. Malaria transmission in the
state is perennial with incidence rate of between 10 – 35%
and peak season coinciding with the rainy season, running
between March and October every year. Children and
pregnant women are the most affected by malaria. There
are about 382 primary health centres (PHCs), managed by
the LGAs, 32 secondary health facilities run by state gov-
ernment and two tertiary health facilities owned by the
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of the Nigerian population, Plasmodium falciparum is the
dominant malaria specie in the state, and artemether-
lumefantrine (AL) is first-line drug for the treatment of
uncomplicated malaria since 2005, followed by Artesunate-
amodiaquine (AA) as alternative first line drug. Presently,
a wide range of ACT is registered in Nigeria for the
first line treatment of uncomplicated malaria, such as
dihydroartemisinin-piperaquine (DHAPQ) and artesunate-
mefloquine (ASMQ) [11]. The state is one of the most im-
portant sources of drugs supply in Africa, due to the pres-
ence of the popular ‘Bridge-Head’ market, a known center
of drug trade, located in Onitsha, the largest commercial
city in the state.
Study sites and setting
The study was carried out in two sites of a federal insti-
tution, the Nnamdi Azikiwe University (NAU). These in-
clude, NAU Medical Center (NAUMC) located at Awka,
the state capital and NAU Teaching Hospital (NAUTH),
Nnewi, the second largest commercial city in the state.
The sites represent primary/secondary and tertiary
healthcare facilities involved in malaria treatment, and
were selected because of the opportunities they present
for collecting quality and reliable data.
The NAU Medical Center is a healthcare facility which
primarily provides outpatient services in a university com-
munity of about 50,000 people, as the catchment popula-
tion. Significant number of the Awka community also
accesses care at the facility. It has about 10 medical officers
who provide clinical services to patients in addition to
nurses, pharmacists, laboratory officers and other health
workers. The center has a functional laboratory which
provides microscopy and RDT services. There are 10 in-
patient beds, which are used to provide brief admissions
for emergency cases. Over 10,000 outpatient cases are
treated annually at the facility. The supply of anti-malarial
drugs is carried out through a process that is based on a
procurement guideline. Donors also provide support
through donations of drugs, such as the Affordable Medi-
cine Facility-malaria (AMFm) drugs, though quantities of
supply are relatively small. Availability of antimalarial drugs
in the facility is said to be regular although, in many occa-
sions there is a limited range of the products at any one
point in time, due to purchasing procedures. Payments are
made by all patients including staff, students and commu-
nity members, who access services at the center. Payment
by the students is deducted from fees paid in advance.
NAUTH is a 500-bed tertiary healthcare facility provid-
ing a variety of specialized clinical and teaching services. It
is the main referral public health facility in the state run
by the federal government. As at 2010, the hospital had
total staff strength of about 2400 workers, spread across
the various clinical and non- clinical departments;comprising over 300 doctors, 400 nurses and 62 pharma-
cists, including intern pharmacists. There are 15 wards
with estimated 80% bed occupancy. The general out-
patient department (GOPD) attends to over 12,000 out-
patient visits annually. Patients pay for services and their
drugs at the point of delivery.
Study design and data collection
A descriptive cross-sectional study was conducted, based
on retrospective cohort event monitoring of patients
treated for uncomplicated malaria in the course of med-
ical practice. Facilities were selected to ensure availability
of adequate patient load and coverage, and the need to
recruit large enough patients in a short period. Hospital
records of patients diagnosed or treated for uncompli-
cated malaria, within a three month period of between
January and June 2013, were collected and audited. Cases
of severe/complicated malaria and pregnant women were
excluded. Two pharmacy graduates were trained to extract
and record the data from the patients’ records into a pre-
designed Excel data form. Individual patient-level records
and prescription were collected for each outpatient treated
at the facilities. Collected data included demographics,
diagnosis, laboratory tests results, drugs prescribed, num-
ber of drugs, cost of drug prescription and co-prescribed
medications, over the study period. Medication doses and
route of administration were not documented, but the
drugs were prescribed and dispensed in age-related doses.
Pre-tested semi-structured questionnaires of 15 ques-
tions were distributed to the prescribing physicians in
selected facilities, to assess their prescribing intent in
the treatment of uncomplicated malaria, in terms of the
use of laboratory services, antimalarial drug-use and
prescription pattern.
Data management and analysis
Data was double entered, cleaned and managed with
Excel spreadsheet. Analysis was carried out for diagnos-
tic approaches, (use of microscopy and/or RDT), use of
ACT, monotherapy, concomitant medication and cost of
medication. Prescriptions were categorised into ACT
and mono therapy. Analysis was carried out at whole fa-
cility level (facilities are located in the same state) and
then separately for individual facility, to assess the differ-
ences in treatment pattern between the facilities in con-
forming to malaria treatment guidelines. Conformity to
treatment guidelines was on the basis of laboratory diag-
nosis, use of ACT and rational use of drugs.
Data were collected using Excel spreadsheet and statis-
tical analysis was performed using SPSS version 16
(SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 for
Windows, (GraphPad Software, San Diego California
USA). Association between variables of interest and the
prescription of antimalarial drugs were estimated using
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used to determine association between categorical vari-
ables, independent student’s t-test for continuous vari-
ables, and univariate analysis to predict the prescription
of ACT and concomitant medications. Statistical signifi-
cance was set at p = 0.05.
Ethical considerations
The study obtained approval from the NAUTH Ethical
Committee as part of a larger study on the pharmacoe-
conomics of malaria treatment in Nigeria. Each doctor’s
consent was obtained to participate in the questionnaire
survey. The study did not involve direct patient contact
hence patient consent was not necessary.
Results
Study characteristics and malaria diagnosis
A total of 7949 outpatient visits were identified, out of
which 2171(27.3%) cases were treated for uncomplicated
malaria. Ninety-four (4%) records were excluded due to ei-
ther severe malaria or incomplete/missing information on
variables of interest. 49% (1066) of those treated for mal-
aria was sent for laboratory examination while the rest,
51% (1105) was based on presumptive diagnosis. 48% of
laboratory diagnosis tested slide positive while 52% tested
negative. Only the tertiary health facility reported the use
of RDT. Figure 1 shows the graphic presentation of selec-
tion process. The proportion of uncomplicated malaria
cases was higher at the medical center, 47% (1261/2674)
compared to the teaching hospital, 17% (910/5252).Malaria Suspected/ treate







Presumptive  malaria 
treatment
n = 1105 (51%)
Slide neg
n = 54
Figure 1 Schematic summary of selected malaria cases included in thCharacteristics of cases finally analyzed (Table 1)
shows that overall, females (56%) outnumbered males
(43%). Gender disparity was higher at the teaching hos-
pital than the medical center where females, 65% out-
numbered males, 35%, (p <0.0001). Most cases (62%) fall
between 19 years and above, at a median age of 23 years,
ranging from one month to 98 years. Children under
5 years accounted for 10% of total cases. The proportion
of children under five years was higher at the teaching
hospital, 20% (181/910) compared to the medical center,
2.6% (33/1261). The proportion of ACT prescribed at
the medical center (95%) was significantly higher than
the teaching hospital, (91%, p < 0.003).
Antimalarial drugs prescription pattern
Table 2 shows the distribution of antimalarial drugs (in-
cluding co-medication) prescribed by facility. A total of
2,171 drug encounters were analyzed. Of these, 93%
(2027) contained an ACT, while 7% (144/2171) was pre-
scribed monotherapy. There were some variations in
prescription pattern between the facilities. The propor-
tion of patients who received ACT compared to mono-
therapy at the medical center, 95% (1198/1262) was
significantly higher than the proportion prescribed at the
teaching hospital at 91% (828/910, p = 0.003). Overall, the
pattern of prescription shows that AL, at 51% (1024/2027)
was the most prescribed ACT at both health facilities,
followed by DHAPQ, 17% (339/2027) and ASAQ 12%.
While this pattern was similar at the medical center, it dif-
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Chi square difference p-value
Total number of outpatients visits 7926 2674 5252 - -
Proportion of malaria cases 2171 (27) 1261 (47) 910 (17) 729.8 0.0001***
Mode of diagnosis
Microscopy 939 (43) 650 (52) 288 (32) 9.95 0.0016**
RDT 128 (6) - 128 (14) - -
Presumptive 1105 (51) 611 (48) 494 (54) 0.875 0.3497
Gender
Female 1207 (56) 635 (50.4) 573 (63.0) 42.09 0.0001***
Male 942 (43) 626 (49.6) 316 (34.7) - -
Unknown 22 (1.0) - 21 (2.3) - -
Age category (yrs) 20.29 0.0001***
Under 5 214 (10) 33 (2.6) 181 (20) - -
5 – 12 52 (2) 22 (1.7) 30 (3) - -
13 – 18 104 (5) 78 (6.2) 36 (3) - -
19 and above 1354 (62) 1026 (81.4) 330 (36) - -
Unknown 447 (21) 102 (8.0) 343 (38) - -
Median age of cohort (range) 23 (0.1 – 98) 23 (1 – 82) 24 (0.1 – 98)
Antimalarial drugs
ACT 2027 (93) 1198 (95) 828 (91) 13.02 0.0003***
Monotherapy 144 (7) 63 (5) 81 (9) - -
**= significant: ***= very significant: ****= highly significant.
Table 2 Distribution of antimalarial drugs and co-medication prescribed by facility






Chi square difference P = value
Artemisinin-based combinations (ACTs) 2027 (93) 1198 (95) 829 (91) 13.02 0.0003***
Artemether-lumefantrin 1024 (50.5) 647 (54) 377 (45.5) - -
Artesunate-amodiaquine 244 (12) 206 (17.2) 38 (4.5) - -
Artesunate-mefloquine 232 (11.5) - 232 (28) - -
Artesunate-pyridoxine + pyrimethamine 188 (9.3) 56 (4.7) 132 (16) - -
Dihydroartemisinin-piperaquine 339 (16.7) 289 (24.1) 50 (6) - -
Mono-therapy 144 (7) 63 (5) 81 (9) 13.02 0.0003***
Artesunate 42 (29.2) 7 (11.1) 35 (43.2) - -
Amodiaquine 14 (9.7) - 14 (17.3) - -
Proguanil 15 (10.4) 1 (1.6) 14 (17.3) - -
Quinine 6 (4.2) 6 (9.5) - - -
Sulphadoxine + pyrimethamine 67 (46.5) 49 (77.8) 18 (22.2) - -
Proportion of co-medication n (%) 1722 (97) 1248 (99) 864 (95) 32.37 0.0001***
Analgesics 1722 (79) 1124 (89) 598 (66) 176.8 0.0001***
Vitamin preparations 1364 (63) 993 (79) 371 (41) 324.8 0.0001***
Antibiotics 1084 (50) 721 (57) 363 (40) 63.18 0.0001***
***= very significant.
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methamine (ASSP) were the second and third most pre-
scribed ACT respectively, after AL. Highest proportion of
monotherapy was prescribed as SP, 47% (67/144), followed
by artesunate monotherapy (AS), 29.2%. The pattern,
however reversed at the teaching hospital where AS, 43%
(35/81) was the most prescribed monotherapy, followed
by SP, 22% (18/81). More monotherapy (9%) was pre-
scribed at the teaching hospital compared to the medical
center (5%). Prescription pattern also varied by age and
gender. Higher proportion of SP, 49% compared to other
monotherapy agents was prescribed to females than males,
44%. Similarly more females, 29% received monotherapy
AS than males, 27%.Co-prescribed medication
97% of the patients received at least one co-prescribed
medication, at an average of 4 (±1.5) drugs per prescrip-
tion. Analgesics were the most commonly prescribed
co-medication given to 79% (1722/2171) of the cohort,
followed by vitamin preparations (63%), and antibiotics
(50%). The pattern varied significantly between the facilities
and across categories (Tables 2 and 3). Proportion of co-
prescribed medications was higher at the medical center,
99% compared to the teaching hospital, (95%, p < 0.0001)
(Table 2). This was similar for the most commonly
co-prescribed medications at the facilities. Majority, 57% of




Artemisinin-based combination therapy (ACT) 1127 (93)
Artemether-lumefantrin (AL) 568 (50)
Artesunate-amodiaquine (ASAQ) 113 (10)
Artesunate-mefloquine (ASMF) 168 (15)
Artesunate-sulphadoxine + pyrimethamine (ASSP) 115 (10)
Dihydroartemisinin-piperaquine (DHAPQ) 163 (14)
Monotherapy 80(7)
Sulphadoxine + pyrimethamine (SP) 39 (49)
Artesunate (AS) 23 (29)
Amodiaquine (AQ) 7 (9)




Vitamin preparations 701 (56)
Antibiotics 569 (47)
NAUMC = Nnamdi Azikiwe University Medical Center, NAUTH = Nnamdi Azikiwe Uniantibiotics compared to children between 5 and 12 years
(37%, p <0.001) and adults, (53%; p < 0.05) (Table 3).
Prescription pattern in children under 5 years
Of the 214 under 5-year old children in this study, 85%
(182) received ACT. AL, 70% (128/182) was the most pre-
ferred antimalarial drug of choice, followed by artesunate-
amodiaquine (ASAQ), 16%. The use of monotherapy
occurred most in this group compared to other age cat-
egories, and amodiaquine, 38% (12/32) was the most com-
monly prescribed monotherapy, followed by monotherapy
artesunate (AS), 34%. Majority, 57% of the under-5 year old
children were more likely to be co-prescribed antibi-
otics than children between 5 and 12 years (37%,
p <0.001) and adults, (53%; p < 0.05) (Table 3). In many
cases, the antibiotics were prescribed in combination with
cough medications. Co-prescription with analgesics and
vitamin preparations was also common in children.
Costs of medication
Table 4 shows that overall, the median cost of medication
(including co-medication) per patient at the two facilities
was N1160 (US$7.48) . Medication cost of treatment per
patient at the tertiary hospital, N1378 (US$8.89) is about
27% higher than at medical center N1083 (US$6.99).
Between the groups, median cost of medication was
lowest in children 5 – 12 years, N776 (US$5.01), com-
pared to adults 19 years and above, N1160 (US$7.83). The












881(94) 182(85) 45 (87) 101(97) 1286 (95)
446 (51) 128 (70) 31 (69) 50 (50) 624 (49)
125 (14) 29 (16) 3 (7) 15 (15) 184 (14)
64 (7) - - 5 (5) 113 (9)
72 (8) 18 (10) 11 (24) 9 (9) 82 (6)
174 (20) 7 (4) - 22 (22) 283 (22)
61(6) 32(15) 7 (13) 3 (3) 70 (5)
28 (44) 4 (13) 2 (29) 2 (67) 44 (63)
17 (27) 11 (34) 1 (14) 1 (33) 19 (27)
6 (9) 12 (38) 1 (14) - -
4 (6) - 1(14) - 5 (7)
6(14) 5 (16) 2 (29) - 2 (3)
783 (83) 119 (59) 34 (54) 87 (84) 1148 (85)
646 (69) 106 (52) 35 (56) 69 (66) 951 (70)
502 (53) 115 (57) 23 (37) 59 (57) 720 (53)
versity Teaching Hospital.
Table 4 Medication cost of treatment
Treatment cost (Naira)
Variable Median Range Mean 95% CI
Antimalarial drugs
ACT 1176 45 – 41520 1587 1511 – 1663
Mono-therapy 750 30 – 8485 1158 927 – 1389
Gender
Male 1158 72 – 41520 1340 1220 – 1460
Female 1110 30 -16010 1499 1403 – 1594
Age group
Under 5 1062 45 – 7760 1151 1024 – 1277
5 - 12 yrs 776 30 – 3734 914 741- 1087.2
13 – 18 1118 150 – 7900 1243 1067 – 1418
19 and above 1160 85 41520 1503 1412 – 2595
Facility 1160 30 – 41520 1559 1486 – 1632
NAUMC 1085 85 – 8000 1171 1135 – 1207
NAUTH 1378 30 – 41520 2101 1940 – 2262
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monotherapy, N750 (US$4.84). It was not possible separ-
ating the cost of malaria component of treatment from
that of co-morbidity due to inadequate documentation on
diagnosis. Hence, medication cost includes the cost of co-
morbidity.
Questionnaire distribution recorded 100% response.
While every respondent would often request for labora-
tory test for malaria before treatment, they would also
sometimes treat by clinical diagnosis alone. Some of the
reasons given for presumptive diagnosis include, confi-
dence in their ability to diagnose malaria without labora-
tory test (100%), severity of symptom (80%), patient load
and lack of waiting time (60%), and previous experience
with particular symptom/s (60%). All prescribers (100%)
would sometimes prescribe antimalarial drugs in slide-
negative results for a variety of reasons; need to prevent
malaria infection (40%), unreliable result (60%), and un-
aware of result (40%). All respondents were aware of
availability of malaria treatment guidelines and all would
use AL as the preferred ACT of choice for its efficacy
and minimum side effects. All doctors use ACT based
on recommended guidelines.
Discussion
This study illustrates practical realities in the treatment
of uncomplicated malaria in public health facilities in
Nigeria, which has implications for the implementation
of malaria treatment guidelines. Findings reflect prac-
tices as they relate to the test and treat policy of malaria
control. The predominance of the female gender is con-
sistent with many studies [7,8,18,19], where females out-
numbered males in health facilities compared to theretail sector. This observation agrees with the suggestion
that females make more use of public health facilities
than males, who tend to prefer medicine outlets [11].
The finding also implies that women suffer more from
malaria attack than males in the study area. The higher
proportion of malaria cases at the medical center, (a pri-
mary/secondary health facility) is easily explained by the
fact that primary health facilities are the main sources of
treatment for uncomplicated malaria [9]. The 27% mal-
aria incidence in this study would suggest a declining in-
cidence compared to previous reports of 60% incidence
for outpatients consultations in Nigeria [20].
The use of laboratory diagnosis for malaria treatment in
the two facilities was limited to 49%, relying substantially
on presumptive diagnosis, contrary to the test and treat
recommendations of current guidelines. This indicates
high incidence of over-diagnosis and over-use of antimal-
arial drugs, in view of the degree of inaccuracy associated
with presumptive malaria treatment [15,21,22]. The find-
ing corroborates previous studies in Nigeria and other
African countries which have reported widespread limited
use of laboratory diagnosis in malaria treatment, even with
the presence of diagnostic tools [3,8,15,21]. It reflects the
level of confidence and popularity to which prescribers at-
tach to presumptive malaria treatment, as was confirmed
by doctors’ responses. This is consistent with findings by
Onwujekwe et al. in 2009 and Uzochukwu et al., in 2010,
in which over 80% of providers at both hospital and non-
hospital alike, are confident in clinical diagnosis of malaria
[10,21]. The study by Meremikwu et al. in 2007, reported
laboratory test rate of 45% [8], while Uzochukwu et al. re-
ported a rate of 51.1% in Enugu [21], suggesting no signifi-
cant improvement since 2010. The level of confidence in
clinical diagnosis should be considered unrealistic in view
of the evidence to the contrary and the high incidence of
inaccuracy and wastages associated with presumptive mal-
aria treatment [22]. Consequences include missed diagno-
sis of other illnesses and increased risk of morbidity [23].
This underscores the need for intensified efforts at promot-
ing the use of diagnostic approach to malaria treatment at
the facilities, through regular education programmes for
health workers [3]. In addition, findings also suggest that
low utilisation of diagnostic test was due to high patient
load and hence, lack of waiting time for receiving the result
of the test, which should be noted for improvement. The
benefit of RDT in terms of rapid delivery of results ad-
dresses this problem. Patients were treated presumptively
even with the availability of laboratory tools in the facilities.
The proportion of patients who received antimalarial drugs
with slide negative results was quite substantial, consider-
ing the enormous wastages that accompany this. This was
justified by the prescribers for a number of reasons; (1) un-
reliability of laboratory results due to poor laboratory re-
agents, (2) RDT insensitivity (further studies may be
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sults. Previous studies in the area have similarly reported
unreliability of laboratory results as a major cause of treat-
ment of slide negative results, especially with RDT [10,21].
Hence, the study showed limited use of RDT compared to
microscopy, even when it was available in both facilities,
confirming the lack of trust of providers on RDT test re-
sults. This should worry policy considering the inter-
national focus on the use of RDT and implication for the
goal of TTT policy [2,3]. Further investigation on the sup-
ply of quality RDT products for intervention is required, to
ensure reliability of its results and the success of the test
and treat policy. There is clear need for improved labora-
tory standards for malaria diagnosis, which can be achieved
through a simple system of quality control. Continuous
education of providers through regular seminars and work-
shops, on the benefits of confirmatory diagnosis cannot be
over-emphasized. The extent of treatment of slide negative
results and doctors responses to the issue calls for strat-
egies to enhance their respect for negative results. There is
need to enforce quality control to enhance reliability of
diagnostic results. Benefits of confirmatory diagnosis and
consequences of poor laboratory practices should be part
of the regular updates to boost the confidence of pre-
scribers in adhering to laboratory diagnosis.
Pattern of prescription in the study shows a clear pref-
erence for ACT, as the drug of choice for uncomplicated
malaria at the two health facilities. This indicates high
conformity to policy recommendation. The preference
for AL, the policy first line drug at both facilities indi-
cates providers’ confidence in the efficiency of the regi-
men, as was confirmed by questionnaire responses. The
pattern appears similar to what obtained in the retail
sector in the area, where DHAPQ was also found to be
the second most prescribed antimalarial drug/ACT [11].
However, the greater dominance of ACT in this study,
95% compared to the retail sector 73%, is consistent with
findings that public health facilities conform more to
policy guidelines than the retail sector [11]. The retail
sector is dominated by self-medication, which is charac-
terised by high incidence of monotherapy use. The fact
that the medical center uses more ACT than the tertiary
health facility can be explained by the predominance of
children and female cases at the later in which mono-
therapy was most prescribed for prophylaxis. Preference
for AL is consistent with many study findings in both
Nigeria and other African countries [3,11,18]. Similar to
the retail sector [11], the use of AA which was the pol-
icy’s alternative policy drug, was limited in this study.
This was also explained by the reported safety concerns
associated with the use of AA, especially in adults
known to present with varying degrees of side effects
[11]. The prescription of SP, mostly for prophylaxis in
the study conforms to guidelines for its use inIntermittent Preventive Treatment in pregnancy and
children (IPTp and IPTc). However, the use of AS and
quinine is not in line with policy and therefore should
be of concern.
The use of an average of four drugs per prescription in
this study suggests high incidence of co-medication, go-
ing by the WHO recommendation of two to three drugs
for developing countries. This gives an indication of
poly-pharmacy in the studied facilities, increasing the
risks of drug interactions, adverse drug reactions and
high cost of treatment for the patients. Co-medication
was higher at the medical center with five drugs per pre-
scription. While poly-pharmacy may be justified in some
cases by the significant number of co-morbidity, propor-
tion of co-medication with vitamin preparations and an-
tibiotics has implications for the safety and efficacy of
antimalarial drugs. The fact that many of the prescrip-
tions were on the basis of presumptive diagnosis, made
this situation more critical, contributing to further wast-
ages. There are concerns with co-administration of vita-
min preparations with ACT in view of the antioxidant
effects of vitamin compounds such as zinc, iron, vitamins
C and E, on artemisinin compounds [24,25]. This may
lead to reduced availability and hence reduced efficacy of
the agents, and in consequence, contribute to treatment
failures and increasing resistance of the Plasmodium. It
has been advised that if needed, vitamins preparations
could be used after completing the ACT dose. The use of
antibiotics in absence of co-morbidity also has implica-
tions for safety, in view of their known side effects, which
may be wrongly attributed to the antimalarial drugs. Co-
prescription with antibiotics occurs usually as ‘a cover’ for
potential co-infection which would suggest that the pre-
scriber is less confident of actual diagnosis, or prevent
subclinical infection becoming manifest [26]. Hence, many
prescriptions were secondary to diagnosed infections.
Similar findings were reported from a study in Tanzania,
for patients with a history of cough in the last 48 hours,
for which antimalarials were prescribed even with negative
results [15].
Although this study did not assess the appropriateness
of antibiotics use, the likelihood of overtreatment with an-
tibiotics, similarly reported in many other studies [26,27]
had led to the call for better diagnostic approach to non-
malarial fevers and development of guidelines for manage-
ment of such illnesses, which should be incorporated into
malaria case-management trainings for health workers [3].
This recommendation should be treated as priority to en-
hance the rational use of both antimalarial drugs and
antibiotics.
The total cost of medication per prescription (including
co-medication) in this study, which showed a median of
US$7.48, is about 2.6 times higher than similar cost ob-
tained for retail outlets, (US$2.90) in a study undertaken
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is consistent with reported higher cost of care in public
health facilities, due to the cost of more professional ser-
vices [9]. This relatively higher cost of medication in pub-
lic health facilities has remained as one of the major
factors that inform the preference for the retail sector by a
significant proportion of patients’ population for malaria
treatment [9]. The higher cost of medication at the tertiary
health facility may be explained by the higher cost of ex-
pert care at a tertiary/referral center.
Treatment practices varied notably between the two
facilities, in terms of patients’ characteristics. The p-
value shows significance in many of the variables, indi-
cating differences in prescribing practices of doctors
between the facilities. These differences highlight the
variation in prescribing cultures between similar facilities
across the country, suggesting differences in dissemin-
ation of anti-malaria training information. The differ-
ences may also point to the levels of exposure to malaria
treatment practices. Regular updates therefore provide
opportunity for promoting appropriate malaria treat-
ment practices in these health facilities [18]. Indicators
suggest better performances at the teaching hospital
compared to the medical center, which is consistent with
reports that prescribers in tertiary institutions tend to
adhere more to national treatment guidelines [28]. The
presence of more specialized doctors at the tertiary cen-
ter, who are probably better exposed to information than
those at the medical center, may explain this.
Limitations
A few limitations are reported in this study. The selected
sample facilities may reflect a potential bias towards
public health facilities with high patient load. However,
considering the health-seeking pattern for malaria treat-
ment in Nigeria, where majority of cases are treated in
the public sector compared to the private sector [29], se-
lected facilities may be a likely representative of study
population. Comprehensive diagnostic information was
not collected due to inadequate documentation of pa-
tient diagnosis, to better inform the use of antibiotics
and other concomitant medications. The study did not
assess the appropriateness of prescription dosages and
weights. However, most of the ACTs were administered
according to age-related dose packages and hence most
likely to conform to patients’ ages and weights. While
the study may be limited in scope in terms of the num-
ber of facilities studied, findings reflect, to a greater ex-
tent the practice pattern in the sector, considering the
similarity in many ways, of the findings of previous studies
carried out in the area [7,8,10,21] and other settings [26].
However, the study needs to be scaled-up to strengthen
the findings for enhanced policy interventions for im-
proved malaria case management.Conclusion
Eight years after the change in antimalarial treatment
policy, there is substantial compliance to policy on the
use of ACT, as the first line treatment for uncomplicated
malaria at the two health facilities. However, treatment
practices are substantially characterised by limited use of
laboratory diagnosis, relying mostly on presumptive treat-
ment, over-diagnosis, over-treatment, co-medication and
lack of routine information on malaria treatment, to guide
effective implementation of treatment guidelines. These
create the risk of developing parasite resistance and treat-
ment failures, undermining the goals of malaria treatment
policy. There is therefore a wide scope for improved diag-
nostic and treatment practices at the two health facilities,
to enhance the efficiency of malaria case management.
Targeted intervention through promotion and regular
education of providers on appropriate malaria treatment
practices is imperative, based on recommended guidelines
and the test and treat policy. This would surely improve
confirmatory diagnosis and rational drug prescribing, to
achieve the goals of malaria case management. There is
also the need to ensure adequate supply of quality and
sensitive diagnostic equipments, which is critical to the
success of the ‘test and treat’ policy of malaria case
management.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CCE conceived and designed the study, collected and analyzed data, wrote
the manuscript. MO and COE assisted in study design, data interpretation
and manuscript review. All authors read and approved final manuscript.
Acknowledgement
Authors appreciate the support of various heads and staff of relevant
departments in the study facilities, for their kind support in providing all
necessary documents for the study, ensuring successful collection of data
from their respective facilities. The support of pupil and student pharmacists
Nwabugo and Jeniffer in data collection and documentation is well
acknowledged and appreciated.
Author details
1Department of Clinical Pharmacy & Pharmacy Management, Faculty of
Pharmaceutical Sciences, Nnamdi Azikiwe University Awka Agulu campus,
Agulu, Nigeria. 2Department of Clinical Pharmacy & Pharmacy Management,
Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
3Department of Pharmaceutical Microbiology & Biotechnology, Faculty of
Pharmaceutical Sciences, Nnamdi Azikiwe University Awka, Agulu campus,
Agulu, Nigeria.
Received: 31 July 2014 Accepted: 10 October 2014
Published: 14 November 2014
References
1. WHO: Antimalarial Drug Combination Therapy: Report of a WHO Technical
Consultation. Geneva, Switzerland: World Health Organization; 2001.
2. WHO: Guidelines for the Treatment of Malaria (Second Edition). Geneva,
Switzerland: World Health Organization; 2010.
3. Zurovac D, Githinji S, Memusi D, Kigen S, Machini B, Muturi A, Otieno G,
Snow R, Nyandigisi A: Major improvements in the quality of malaria
case-management under the “test and treat” policy in Kenya. PLoS One
2014, 9(3):e92782. doi:10.1371/journal.pone.0092782.
Ezenduka et al. Journal of Pharmaceutical Policy and Practice 2014, 7:15 Page 10 of 10
http://www.joppp.org/content/7/1/154. WHO: World Malaria Report 2012. Geneva, Switzerland: WHO; 2012.
5. Zurovac D, Ndhlovu M, Rowe AK, Hamer DH, Thea DM, Snow RW:
Treatment of paediatric malaria during a period of drug transition to
artemether-lumefantrine in Zambia: cross sectional study. BMJ 2005,
331:734.
6. Hensen B, Paintain LS, Shretta R, Bruce J, Jones C, Webster J: Taking stock;
provider prescribing practices in the presence and absence of ACT
stock. Malar J 2011, 10:218.
7. Mangham LJ, Cundill B, Ezeoke O, Nwala E, Uzochukwu C, Wiseman V,
Onwujekwe O: Treatment of uncomplicated malaria at public health
facilities and medicine retailers in southeastern Nigeria. Malar J 2011,
10:155. doi:10.1186/1475-2875-10-155.
8. Meremikwu M, Okomo U, Nwachukwu C, Oyo-Ita A, Eke-Njoku J, Okebe J,
Oyo-Ita E, Garner P: Antimalarial drug prescribing practice in private and
public health facilities in south-east Nigeria: a descriptive study. Malar J
2007, 6:55.
9. Chuma J, Abuya T, Memusi D, Juma E, Akhwale W, Ntwiga J, Nyandigisi A,
Tetteh G, Shretta R, Amin A: Reviewing the literature on access to prompt
and effective malaria treatment in Kenya: implications for meeting the
Abuja targets. Malar J 2009, 8:243. doi:10.1186/1475-2875-8-243.
10. Onwujekwe O, Uzochukwu B, Dike N, Uguru N, Nwobi E, Shu E: Malaria
treatment perceptions, practices and influences on provider behaviour:
comparing hospitals and non-hospitals in south-east Nigeria. Malar J
2009, 8:246.
11. Ezenduka CC, Ogbonna BO, Ekwunife OI, Okonta MJ, Esimone CO: Drugs
use pattern for uncomplicated malaria in medicine retail outlets in
Enugu urban, southeast Nigeria: implications for malaria treatment
policy. Malar J 2014, 13:243. doi:10.1186/1475-2875-13-243.
12. Philllips-Howard PA, Wannemuehler KA, Ter Kuile FO, Hawley WA, Kolczak
MS, Odhacha A, Vulule JM, Nahlen B: Diagnostic and prescribing practices
in peripheral health facilities in rural Western Kenya. Am J Trop Med Hyg
2003, 68(Suppl 4):44–49.
13. White NJ, Olliaro PL: Strategies for prevention of antimalarial drug
resistance: rationale for combination therapy for malaria. Parasitol Today
1996, 12:399–401.
14. WHO: The use of antimalarial drugs: report of a WHO informal consultation
13–17 November 2000. Geneva: World Health Organization; 2001. WHO/CDS/
RBM/2001.33.
15. Reyburn H, Ruanda J, Mwerinde O, Drakeley C: The contribution of
microscopy to targeting antimalarial treatment in a low transmission
area of Tanzania. Malar J 2006, 5:4. doi:10.1186/1475-2875-5-4.
16. WHO: Antimalarial Drug Combination Therapy: Report of a WHO Technical
Consultation. Geneva, Switzerland: World Health Organization; 2001.
17. Federal Republic of Nigeria: National Antimalarial Treatment Policy. Abuja,
Nigeria: FMOH, National malaria and Vector Control Division; 2005.
18. Sears D, Kigozi R, Mpimbaza A, Kakeeto S, Sserwanga A, Staedke SG, Chang
M, Kapella BK, Rubahika D, Kamya MR, Dorsy G: Anti-malarial prescription
practices among outpatients with laboratory-confirmed malaria in the
setting of a health facility-based sentinel site surveillance system in
Uganda. Malar J 2013, 12:252. doi:10.1186/1475-2875-12-252.
19. Thwing JI, Njau JD, Goodman C, Munkondya J, Kahigwa E, Bloland PB,
Mkikima S, Mills A, Abdulla S, Kachur SP: Drug dispensing practices during
implementation of artemisinin-based combination therapy at health
facilities in rural Tanzania, 2002–2005. Trop Med Int Health 2011, 16:272–279.
20. FMOH: Situational Analysis of Malaria Control in Nigeria. Abuja: Federal
Ministry of Health; 2000.
21. Uzochukwu BS, Chiegboka LO, Enwereuzo C, Nwosu U, Okoroafor D,
Onwujekwe OE, Uguru NP, Sibeudu FP, Ezeoke OP: Examining appropriate
diagnosis and treatment of malaria: availability and use of rapid
diagnostic tests and artemisinin-based combination therapy in public
and private health facilities in south east Nigeria. BMC Public Health 2010,
10:486.
22. Chitaka R, Khare AK, Brickling C: Prescribing policy for antimalarials.
Afr Health 1998, 20:2–5.
23. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O,
Saganda K, Shao J, Kitua A, Olomi R, Greewood BM, Whitty CJ:
Overdiagnosis of malaria in patients with severe febrile illness in
Tanzania: a prospective study. BMJ 2004, 329:1212.
24. Oreagba AI, Ashorobi RB: Interactions between retinol and some
established antimalarials in Plasmodium nigeriensis infection in mice.
Int J Pharmacol 2007, 3:270–274.25. Ganiyu KA, Akinleye MO, Tayo F: A study of the effect of ascorbic acid on
the antiplasmodial activity of artemether in Plasmodium berghei
infected mice. J Appl Pharm Sci 2012, 2:96–100.
26. Dodoo ANO, Fogg C, Asiimwe A, Nartey ET, Kodua A, Tenkorang O,
Ofori-Adjei D: Pattern of drug utilization for treatment of uncomplicated
malaria in urban Ghana following national treatment policy change to
artemisinin-combination therapy. Malar J 2009, 8:2. doi:10.1186/1475-2875-8-2.
27. Mtove G, Hendriksen IC, Amos B, Mrema H, Mandia V, Manjurano A, Muro F,
Sykes A, Hildenwall H, Whitty CJM, Reyburn H: Treatment guided by rapid
diagnostic tests for malaria in Tanzanian children: safety and alternative
bacterial diagnoses. Malar J 2011, 10:290.
28. Gbotosho GO, Happil CT, Ganiyu A, Ogundahunsi OA, Sowumi A, Oduola
AM: Potential contribution of prescription practices to the emergence
and spread of chloroquine resistance in south-west Nigeria: caution in
the use of artemisinin combination therapy. Malar J 2009, 1–8.
29. Onwujekwe O, Ojukwu J, Uzochukwu B, Dike N, Ikeme A, Shu E: Where do
people from different socio-economic groups receive diagnosis and
treatment for presumptive malaria in south-east Nigeria? Ann Trop Med
Parasitol 2005, 99:473–481.
doi:10.1186/2052-3211-7-15
Cite this article as: Ezenduka et al.: Adherence to treatment guidelines
for uncomplicated malaria at two public health facilities in Nigeria;
Implications for the ‘test and treat’ policy of malaria case management.
Journal of Pharmaceutical Policy and Practice 2014 7:15.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
